pharma · Vascular Dementia · Angioimmunoblastic T-cell Lymphoma · NBP
NovaBridge Biosciences drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Portfolio lens on 7 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
NovaBridge Biosciences drug portfolio — 7 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
US regulatory status: approved. Molecular target: DNA (cytosine-5)-methyltransferase 1.
Development asset linked to NovaBridge Biosciences in public FDA and regional records.
Development asset linked to NovaBridge Biosciences in public FDA and regional records.
Development asset linked to NovaBridge Biosciences in public FDA and regional records.
US regulatory status: approved. Molecular target: DNA.
Development asset linked to NovaBridge Biosciences in public FDA and regional records.
Development asset linked to NovaBridge Biosciences in public FDA and regional records.